Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 18.83%
March 31, 2026 19.06%
December 31, 2025 18.48%
September 30, 2025 21.42%
June 30, 2025 23.82%
March 31, 2025 23.12%
December 31, 2024 26.00%
September 30, 2024 25.25%
June 30, 2024 19.79%
March 31, 2024 20.89%
December 31, 2023 22.78%
September 30, 2023 22.38%
June 30, 2023 22.06%
March 31, 2023 22.13%
December 31, 2022 22.38%
September 30, 2022 21.87%
June 30, 2022 20.62%
March 31, 2022 20.08%
December 31, 2021 20.59%
September 30, 2021 19.71%
June 30, 2021 25.57%
March 31, 2021 25.00%
December 31, 2020 27.33%
September 30, 2020 27.29%
June 30, 2020 25.56%
Date Value
March 31, 2020 27.06%
December 31, 2019 27.78%
September 30, 2019 27.52%
June 30, 2019 27.23%
March 31, 2019 27.24%
December 31, 2018 27.23%
September 30, 2018 27.29%
June 30, 2018 27.33%
March 31, 2018 27.84%
December 31, 2017 37.75%
September 30, 2017 37.33%
June 30, 2017 38.65%
March 31, 2017 38.67%
December 31, 2016 38.65%
September 30, 2016 38.65%
June 30, 2016 38.52%
March 31, 2016 39.15%
December 31, 2015 39.38%
September 30, 2015 38.97%
June 30, 2015 38.45%
March 31, 2015 37.67%
December 31, 2014 37.39%
September 30, 2014 37.12%
June 30, 2014 36.14%
March 31, 2014 34.88%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
IQVIA Holdings, Inc. 26.20%
Medpace Holdings, Inc. 27.56%
Proteome Sciences Plc --
Champions Oncology, Inc. 48.48%
Avantor, Inc. 31.73%